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Abstract
Background: Sclerotherapy is often the primary treatment for peripheral venous malformations. It is mostly sufficient
alone, but can be combined with other endovascular techniques. Despite its mini-invasiveness, it is not without poten-
tially severe complications. Here, we systematically report sclerotherapy complications in trunk and extremity venous
malformations.
Methods: We retrospectively assessed the complications of 127 consecutive patients who had received sclerotherapy
for peripheral venous malformation in our tertiary care unit (January 2007–August 2013). We applied the Clavien–Dindo
classification to grade the severity of complications. We mostly used detergent sclerosants (85.7%), and less often
ethanol (5.7%) or bleomycin (4.2%). In 4.2% of the procedures, we combined glue, coils, endovascular laser or particles
to sclerotherapy.
Results: The overall complication rate per procedure was 12.5%. Most complications (83.3%) were local and managed
conservatively. We encountered four severe complications, all related to blood coagulopathy. Subcutaneous lesion
location and use of ethanol significantly increased the risk of local complications.
Conclusion: Sclerotherapy alone or combined with other endovascular techniques is a safe method for local venous
malformations with moderate risk for conservatively manageable complications. Blood coagulopathy constitutes a risk
for, otherwise rare, severe complications.
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Introduction
Venous malformations (VMs) are the most common
slow-ﬂow vascular malformations. They are present at
birth and grow along with the child. Although at
infancy they may be imperceptible, they have a ten-
dency to expand as a result of any growth stimulus:
hormonal, traumatic, or surgical.1 These morphologic-
ally heterogeneous lesions can occur in any part of
the body and invade any tissue plane, which makes
the symptoms diverse, varying from mild swelling
to recurrent pain episodes, functional impairment,
and life-threatening blood coagulopathy. Coagulation
of stagnant blood in extensive lesions stimulates
thrombin and initiates the conversion of ﬁbrin to
ﬁbrinogen, which leads to localized intravascular coa-
gulopathy (LIC). This entails a risk for both throm-
bosis and bleeding and can rarely progress to
disseminated intravascular coagulopathy (DIC).2 In
contrast to other vascular malformations, among
trunk and extremity VMs, coagulation disorders can
amount to 58%.3
In the past, the main treatment for VMs was surgery.
In recent years, however, the generally preferred treat-
ment has, in many centres, become percutaneous
sclerotherapy.4–12 Extensive and diﬀuse lesions may
not be surgically removable without severe
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disﬁgurement or functional impairment. Moreover,
because sclerotherapy is less invasive and has better
cost-eﬀectiveness, it has become the method of choice,
even for small lesions. Surgery still plays an adjunctive
role, and supplementary sclerotherapy may enhance its
eﬀectiveness.13 Although not always curative, for most
patients, sclerotherapy provides symptom relief.14
At sclerotherapy, the sclerosant is percutaneously
injected into the VM’s venous spaces with ultrasound
or ﬂuoroscopy guidance. It causes endothelial damage,
leading to vessel-occlusion and lesion shrinkage. This
occlusion occurs gradually, often necessitating serial
treatments. Sclerotherapy often suﬃces alone, but can
in selected cases be combined with other endovascular
techniques in order to close very large venous spaces or
to control the ﬂow and drainage routes of the VM.
Sclerosants
Ethanol is the most potent agent causing instant endo-
thelial damage and eﬀective vascular closure. In add-
ition, ethanol can diﬀuse into nearby structures and
cause variable degrees of tissue necrosis. Because of
its high toxicity, it can cause the most serious side-
eﬀects and should be used with caution and only by
experienced practitioners.8,15
Detergent sclerosants, sodium tetradecyl sulphate
(STS) and polidocanol, are less potent than ethanol,
but also lower risk for local and systemic complica-
tions. Detergents also cause endothelial damage,
inﬂammation, and ﬁbrosis, but the sclerosing process
occurs more slowly, with possibly a higher tendency
toward recanalization.16 They oﬀer, however, an
eﬀective and less toxic alternative to ethanol with dif-
ferent concentrations and forms (solution and foam)
available. Microfoam, made by mixing the detergents
with air or CO2, is more eﬀective than liquid sclero-
sants.12,16 Additionally, STS and polidocanol cause
less pain than ethanol, which reduces the need for gen-
eral anaesthesia.
Bleomycin was originally approved for oncological
chemotherapies and has since served to control excessive
pleural eﬀusions, as well. Like detergents, bleomycin has
less scerosing potency than ethanol, but has the advan-
tage of causing relatively little swelling. The chemother-
apy-related tendency of bleomycin to cause pulmonary
side-eﬀects has long limited its usage. When treating
VMs, however, bleomycin is administered intralesionally
at much lower doses than for chemotherapy (15 units per
procedure, not exceeding a cumulative dose of 300
units). At such a dosage, no reported cases of pulmonary
ﬁbrosis have occurred.16
Complications
Few articles report sclerotherapy complications in
trunk and extremity VMs (Table 1). Most reported
complications are minor or local, but also systemic
complications exist.17 Common sclerotherapy compli-
cations are transient hemoglobinuria and oliguria.18
Furthermore, single case-reports cover sclerotherapy-
related pulmonary embolism,19 reversible cardiac
arrest after polidocanol sclerotherapy,20 fatal cardio-
vascular collapse during ethanol sclerotherapy,21 and
extensive soft-tissue necrosis and infection after STS
and ethanol sclerotherapy.22
Table 1. Studies concerning sclerotherapy complications in trunk and extremity venous malformations.
References Patients (N) Age (y)
Follow-up
(months) Malformation Sclerosant
Complication
rate per
patient (%)
Lee et al.23 87 – 24 mean VM ethanol 28
Tan et al.24 72 31.7 mean 41 mean VM STS 10
Orlando et al.25 39 24 median 18 median VM deep ethanol 12
Orlando et al.26 81 21 median 18 median VM superficial ethanol 21
Gulsen et al.27 19 12.6 mean 2 median VM polidocanol 65
Schumacher et al.28 75 26 mean – VM ethanol gel 12
Hoque et al.29 83 15.1 mean 12 median VM ethanolamine oleate 5
Barbera et al.5 25 22 mean VM foam, glue, coiling 25
Zhang et al.15 138 Children 6 median VM ethanol, bleomycine 29
Bowman et al.30 60 31.7 mean 24 mean VMAVM ethanol, sotradecol, particles,
n-butyl cyanoacrylate,
ethanolamine, onyx
27
Present study 127 21.5 median 35 median VM STS, polidocanol, ethanol,
bleomycine, doxicycline
24
VM, venous malformation; AVM, arteriovenous malformation; STS, sodium tetradecyl sulfate
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Our multidisciplinary team (MDT) uses the
Clavien-Dindo complication classiﬁcation,31–33 origin-
ally developed to assess surgical outcomes. Use of the
same classiﬁcation for sclerotherapy makes compari-
son between these two treatment modalities possible,
also in terms of complications. The Clavien–Dindo
classiﬁcation grades complications on the basis of fur-
ther treatment needed to manage the complication. It
divides complications into conservatively manageable
grades I and II, into surgical, radiological, or endo-
scopic intervention-requiring grade III, into life-threa-
tening grade IV, and fatal grade V complications
(Table 2).
To improve the safety of any treatment, systematic
assessment and reporting of complications are essential.
This reporting must be accurate and objective, avoiding
any subjective descriptions. Our aim is to report on
complications of endovascular treatment for trunk
and extremity VMs and to assess variables aﬀecting
the complication rate.
Materials and methods
Patients
This retrospective study was approved by the Ethics
Committee of Helsinki University Central Hospital.
We reviewed all 127 patients with trunk or extremity
VM undergoing sclerotherapy over a period of 6 years
and 8 months (from 1 January, 2007 to 31 August 2013)
at Helsinki University Central Hospital, a tertiary refer-
ral centre providing care for 1.5 million people. We
deﬁned lesion location and tissue planes involved
from the magnetic resonance imaging (MRI) and ultra-
sonography (US) studies and went through patient rec-
ords to assess complication details, follow-up time, and
possible surgical treatment.
The multidisciplinary team for vascular anomalies,
established in 2002, evaluated each patient and made
recommendations for treatment. The diagnosis was
based on the clinical picture and imaging studies
according to the International Society for the Study
of Vascular Anomalies (ISSVA) 1996 classiﬁcation.34
Indications for sclerotherapy were pain, functional
impairment, swelling, skin induration, and blood coa-
gulopathy, cosmetic indications being few.
Asymptomatic patients and patients with only mild
symptoms were followed up or treated conservatively
by the means of compression garments.
Sclerotherapy procedure
The sclerosants used in the majority of cases were STS
3% (Fibrovein, STD Pharmaceutical, Hereford, UK)
and polidocanol 0.5–3% (Aethoxysklerol, BASE
Pharma, Canberra, Australia) (Table 4). In addition,
we used ethanol 95% and bleomycin 1mg/ml
(Bleomycin, Baxter, Halle/Westfalen, Germany) as
sole agents or combined with other sclerosants, and
once doxycycline 10mg/ml (Doxy 100, Fresenius
Kabi USA, LLC) for a suspected lymphatic malforma-
tion that turned out during the procedure to be venous.
The use of ethanol radically diminished during the
study period. We selected the sclerosant according to
lesion location, depth, and size. We used lower concen-
trations (0.5–1%) of polidocanol for superﬁcial lesions
and STS 3% and polidocanol 3% for deeper lesions.
STS and polidocanol were used as foam. We made the
foam by mixing the sclerosant with air (or CO2)
between two syringes (5 or 10ml) through a three-
way stopcock on average 20 times. The liquid–air frac-
tion was typically 1/3-4, but was not systematically
determined. For wide venous spaces, the foam was pre-
pared with proportionally more air. The aim was to
Table 2. Clavien-Dindo classification for surgical complications.31,32
Management of complication Grade
Any deviation from normal postoperative course without need for pharmacological treatment or
surgical, endoscopic, or radiological interventions. Acceptable therapeutic regiments are: drugs
as antiemetics, antipyretics, analgetics, diuretics, electrolytes, and physiotherapy. Also includes
wound infections opened at bedside
I
Requiring pharmacological treatment with drugs other than acceptable for grade I II
Requiring surgical, endoscopic, or radiological intervention III
Intervention not under general anesthesia IIIa
Intervention under general anesthesia IIIb
Life-threatening complication requiring intermediate care/intensive care-unit management IV
Single-organ dysfunction (incl. dialysis) IVa
Multiorgan dysfunction IVb
Death of patient V
714 Phlebology 31(10)
 at University of Helsinki on December 8, 2016phl.sagepub.comDownloaded from 
achieve as large contact area as possible between the
surfactant molecules and endothelium and to com-
pletely ﬁll the venous spaces. The quality of the foam
was visually checked before injection, and the foam was
used immediately after the generation.
In most procedures (95.8%), we only used percutan-
eous sclerotherapy. Other endovascular techniques, such
as n-butyl-2-cyanoacrylate (NBCA) glue (Histoacryl,
B.Braun, Melsungen, Germany), coils (Interlock,
Boston Scientiﬁc, Boston, or Azur, Terumo,
Somerset, NJ, USA), particles (Bead Block, Terumo,
Somerset, NJ or Embozene, Celo Nova, San Antonio,
TX, USA), or intravascular laser, were combined to
sclerotherapy in 4.2% of the procedures. The indication
for using NBCA glue together with foam sclerosants was
closing very large venous spaces, for which sclerotherapy
alone was considered insuﬃcient. In selected cases, we
used coils for closing the VM’s draining veins prior to
sclerosant administration – for example, if the ﬂuoros-
copy showed sizeable communication of the VM with
the extremity deep venous system. This was to prevent
the sclerosant from disseminating to the normal venous
system. Coils were not deployed into the VM itself. We
utilized arterial PVA embolization together with intrale-
sional foam sclerotherapy for one patient to close feed-
ing arteries of the VM and intravascular laser combined
to glue and sclerosant for another patient with extremely
wide VM. For the two laser procedures, we utilized
radial laser (Biolitec, Jena, Germany) with 10 W power
and 1470nm continuous wave. The ﬁber was inserted to
the malformation through 6 frence introducers at several
points. The energies used were from 4600 to 5200 J and
the withdrawal rate was very slow.
We controlled the blood d-dimer and ﬁbrinogen
prior to the procedure and treated any coagulopathy
in cooperation with a haematologist. Each patient
with extremity lesions was provided with an individu-
ally customized compression garment.
Our sclerotherapy approach closely parallels that
described by Alomari et al.35 Two interventional radi-
ologists performed the procedures. We did the proced-
ures in sterile conditions under local or general
anaesthesia or under intravenous conscious sedation,
depending on patient age, cooperation, and anticipated
pain. For extremity lesions, we ﬁrst applied a tourni-
quet proximal to the lesion to make the venous struc-
tures more visible and to control venous outﬂow. We
cannulated the lesion, under US guidance, with small
needles. After conﬁrming free return of venous blood
from the needle, we injected iodinated contrast under
ﬂuoroscopic control to ensure proper intravenous
access and to deﬁne the extent of the lesion and the
potential draining veins. This also gives an estimate of
the volume needed to ﬁll the lesion. In cases with rapid
venous outﬂow or drainage through potentially danger-
ous routes, we compressed the draining veins by hand
or tourniquet or if necessary occluded them intravascu-
larly with coils before sclerosant injection. We typically
used a double-needle technique, in which we let blood
and the agent exit through a second needle placed else-
where in the lesion.11 This prevents lesion overﬁlling
and ensures that the whole lesion is drained (Figure 1).
To reduce swelling and to facilitate vessel occlusion
in extremity lesions, we placed a compression garment
(23–32mmHg) over the injection site after the proced-
ure. This was typically worn for three days continu-
ously and two weeks during physical activity. We
monitored urine haemoglobin and volume in cases
with extensive lesions.36 We did not administer steroids
routinely. We used them only during treatment of intra-
muscular VMs within conﬁned muscular compart-
ments, in order to diminish swelling and lessen the
Figure 1. Venous malformation in the hand of a 7-year-old boy. (a) The hand before sclerotherapy has a prominent mass in the
hypothenar. (b) T2-weighted fat-saturated axial magnetic resonance image clearly shows pathological venous structures with phle-
bolites and defines lesion extent and tissue planes involved. (c) Fluoroscopy image prior to percutaneous sclerotherapy by double-
needle technique.
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risk for muscle compartment syndrome (iv. dexametha-
sone perioperatively and po. prednisolone for 2–4 days
with decreasing doses). We typically discharged the
patient on the same or the following day and decided
each follow-up schedule individually. If no further
interventions or follow-up visits were scheduled,
we encouraged the patient if symptoms returned to
contact us.
Definition and classification of complications
We designated as complications all disabilities that
developed as a consequence of our treatment. Almost
all patients, however, experienced some postprocedural
pain or swelling, which we considered an expected side-
eﬀect, not a complication, if lasting less than two
weeks. Nor was failure to cure considered a complica-
tion. We graded complications according to the
Clavien–Dindo classiﬁcation (Table 2).
Statistical analysis
An independent statistician analysed the data with
NCSS 8 statistical software. The Chi-Square test or
Fisher’s Exact test was performed for variables possibly
predicting complications (age, lesion location, tissue
plane, sclerosants, and preceding surgery). The
Mann–Whitney U test served for analysis of the
dependence between number of procedures and compli-
cations. For comparison of risks presented by diﬀerent
sclerosants, we conducted a chi-square test between two
groups: a combined detergent group (STS and polido-
canol) and an ethanol group (ethanol as the sole agent
or in combination with any other sclerosants). We con-
sidered a probability level of p< 0.05 as statistically
signiﬁcant.
Results
Table 3 shows descriptive data of the patients (n¼ 127,
age median 21.5) and procedures (n¼ 280, median 2.0).
Lesion size ranged from small subcutaneous lesions to
ones so extensive and diﬀuse that they aﬀected the
whole retroperitoneum or extremity.
Thirty-one (24.4%) patients had a complication with
the overall complication rate per procedure being
12.5%. Three patients developed a complication after
each of two diﬀerent procedures, and one patient devel-
oped two independent complications (allergic reaction
and bleeding) after one procedure.
The tissue plane involved inﬂuenced the complica-
tion rate: risk was signiﬁcantly higher in subcutane-
ously conﬁned lesions than in deeper lesions with an
intramuscular component (p¼ 0.049). The age of the
patient (17 vs> 17 years), number of procedures,
or location of the malformation treated did not signiﬁ-
cantly aﬀect complication risk. Preceding surgical exci-
sion (29 patients) did not elevate the probability of
sclerotherapy complications, nor did any sclerotherapy
complication predict further need for surgical
treatment.
Table 4 shows complication numbers from each
sclerosant. Detergent sclerosants were the choice in
the majority of procedures (85.7%), with equal compli-
cation rates from STS (11.1%) and polidocanol
(11.8%). Bleomycine was only used in four procedures
and caused no complications. Ethanol served as the
sole agent or in combination with other sclerosants in
16 procedures with a complication rate of 31.2%, which
was signiﬁcantly higher (p¼ 0.019) than in the com-
bined-detergent group (STS and polidocanol).
We combined one or several endovascular tech-
niques to percutaneous sclerotherapy for eight patients
in 12 procedures; glue in 10, coils in 4, intravascular
laser in 3, and particles in one procedure.
Table 3. Characteristics of patients and treatments.
N(%) or median (range)
Patients 127
Female 73 (57.5)
Male 54 (42.5)
Age median (range) 21.5 (3.4–76.0)
17 years 47 (37.0)
>17 years 80 (63.0)
Diagnosis
MRI 118 (92.9)
histology 11 (8.7)
only US 8 (6.3)
Lesion location
Lower extremity 62 (48.8)
Upper extremity 50 (39.4)
Trunk 15 (11.8)
Tissue plane
Subcutaneous 59 (46.5)
Intramuscular 64 (50.4)
Intraosseal 5 (3.9)
Intra-articular 4 (3.2)
Intra-abdominal, retroperitoneal 2 (1.6)
Surgery
Previous surgery 29 (22.8)
Surgery after sclerotherapy 10 (7.9)
Sclerotherapy procedures 280
Procedures per patient 2.0 (1–10)
Follow-up, months 35.0 (0–82)
Last visit, months 19.0 (0–80)
MRI, magnetic resonance imaging; US, ultrasound.
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A complication occurred in three of these procedures
where we combined sclerotherapy with glue or with
glue and intravascular laser. All the three complications
were related to blood coagulopathy with an additional
infection in two of them. No complications followed
the use of coils or particles.
According to the Clavien–Dindo classiﬁcation, most
complications (30 cases, 83.3%) were conservatively
managed grade I–II (Table 5), of which the most sig-
niﬁcant were local skin damage (n¼ 12) and prolonged
pain or swelling at the injection site (n¼ 9). We encoun-
tered two deeper skin necrosis, which necessitated skin
grafts (grade IIIa), and additionally, three grade IV and
one grade V complication to be discussed in detail.
Figure 2 shows a grade IIIa complication.
The four grade IV–V complications involved the
three patients with the most complicated and
diﬀuse VMs (Figure 3). Moreover, in all these
patients, the malformation caused severe consumption
coagulopathy.
One paediatric patient (Figure 3, top panel) with an
extensive and diﬀuse retroperitoneal VM, after dorsal
needle puncture of the retroperitoneal lesion, suﬀered
from severe (6 l) intra-abdominal bleeding from the left
phrenic artery. He underwent intravascular emboliza-
tion and recovered after treatment in an intensive care
unit. The main indication for treatment was consump-
tion coagulopathy and DIC which is, after several
sclerotherapy procedures, now under control.
The man in Figure 3 (middle panel) had an extre-
mely extensive VM of the right leg and lower body,
causing hygienic and life quality problems. He had
severe consumption coagulopathy, a ﬁbrinogen level
close to zero, and episodes of life-threatening bleedings
and pulmonary embolism. The malformation was con-
sidered inoperable because of risk for uncontrollable
bleeding. The sclerotherapy-related risk for skin
damage and infection was high and was thoroughly
discussed. Coagulopathy and facilitation for further
surgery were the main indications for sclerotherapy.
After two separate sclerotherapy sessions, he had
severe infection complications. The ﬁrst time, after
sclerotherapy with polidocanol and ethanol combined
with NBCA and laser therapy, he bled at the injection
site and had skin damage followed by infection of the
haematoma and sepsis. He was treated with intraven-
ous antibiotics and prolonged hospitalization in an
intermediate care unit. The second time, after perirectal
foam sclerotherapy combined with NBCA and laser
therapy, he experienced worsening of the DIC, bleed-
ing, sepsis, and abscess formation. He recovered from
both severe infections and has thereafter undergone
several sclerotherapy procedures without complica-
tions. His coagulopathy is now under control, the mal-
formation mass has shrunk, and surgical treatment to
reduce the mass is scheduled.
The woman in Figure 3 (bottom panel) had a wide
and diﬀuse VM covering her entire upper extremity and
axilla. This malformation caused consumption coagu-
lopathy and DIC with chronic need for low-molecular
weight heparin. The main indication for treatment was
that the aﬀected limb was totally unusable, and the goal
was to facilitate further surgery. The procedure was
carefully planned, and the coagulation disorder was
monitored and treated by a haematologist prior to
and during the procedure. The patient underwent
sclerotherapy with percutaneous STS 3% and NBCA
glue. Despite all precautions and treatment of the coa-
gulopathy, the following day she suﬀered a multifocal
intracerebral haemorrhage, which was eventually fatal.
She had had no previous neurological symptoms or
imaging examinations of the brain, and neuropatho-
logical autopsy revealed no predisposing condition for
intracerebral haemorrhage.
Discussion
Our experience indicates that the major risk for severe
complications of the VMs endovascular treatment is
blood coagulopathy. This has not been systematically
reported earlier, although the association of VMs with
blood coagulopathy is well documented.2,3,37 All the
most serious (grade IV and V) complications were, at
least in part, due to blood coagulopathy. Less severe
(grade I–III) complications were associated with super-
ﬁcial lesions and use of ethanol.
Most of the coagulopathy related complications
occurred in procedures with other endovascular tech-
niques (glue or/and laser) combined to percutaneous
sclerotherapy. This is obviously due to the ﬂuctuation
of coagulation factors during the treatment of a wide
VM and may not be associated with any speciﬁc treat-
ment modality. The infection complications, otherwise
very rare in sclerotherapy, were related to the use of
NBCA glue and laser, for which the probable cause
Table 4. Complication numbers for the sclerosants.
Sklerosant Procedures (N) Complications (N)
STS 3% 189 21
Polidocanol 0.5–3% 51 6
Ethanol 95% as sole agent 3 2
Ethanol alone or in
combination
16 5
Bleomycine as sole agent 4 0
Bleomycine alone or in
combination
12 1
Doxycycline 1 1
STS, Sodium tetradecyl sulphate.
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was the glue being a foreign material. We had no com-
plications associated to the coiling of draining veins.
A consequence of the infection complications has
been further development of our treatment guidelines.
We now use antibiotic prophylaxis for patients with
pre-existing skin damage, with an apparent risk for
skin damage or when using glue to close large venous
spaces. In these cases, the foreign material with clotted
Table 5. Descriptions and numbers of complications and details of necessitated managements. Complications classified according to
Clavien-Dindo (Table 2).
Complication Management N Grade
Skin damage Not necessitated 8 I
Pain or swelling or both for> 2 weeks Analgesics and/or compression garment 6 I
Thrombophlebitis outside the malformation Not necessitated 3 I
Unusual pain and transient sensory loss Analgesics 1 I
Unusual swelling and loss of range of joint motion Physiotherapy 1 I
Pain, swelling, skin damage, and loss of range of motion Analgesics, physiotherapy 1 I
Digital loss of range of joint motion Physiotherapy 1 I
Skin damage, infected Antibiotics, per oral 4 II
Allergic reaction Corticosteroids, antihistamine 3 II
Intra-abdominal bleeding, mild Blood transfusion (one unit) 1 II
Deep vein htrombosis at ankle level LMWH medication 1 II
Skin damage Skin graft under local anesthesia 2 IIIa
Bleeding at injection site, sepsis, abscess,
worsening of DIC
Transfusions of blood and coaculation factors,
i.v antibiotics, abscess drainage, ICU treatment
and prolonged hospitalization
1 IV
Bleeding at injection site, skin damage and sepsis Intermediate care-unit treatment, i.v. antibiotics,
long hospitalization,
1 IV
Intra-abdominal bleeding (6 liters) Blood transfusion, intra-arterial embolisation,
ICU treatment
1 IV
Intracerebral hemorhage and exitus 1 V
LMWH, low-molecular-weight heparin; ICU, intensive care unit; DIC, disseminated intravascular coagulopathy.
Figure 2. A previously operated venous malformation with recurrence in the right fourth finger. (a) Skin necrosis after sclerotherapy
with sodium tetradecyl sulphate 3% necessitated skin grafting and was graded as IIIa due to the need for surgical treatment. (b) The
same finger three months after skin grafting.
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blood increases the risk for infection. Treatment of
extensive perirectal or perineal malformations may
require a temporary colostomy. Cooperation with a
plastic surgeon is essential in treating soft-tissue
complications.
Treatment of patients with extensive VMs should be
pre-planned in a multidisciplinary setting and per-
formed in centres with a haematology consultant avail-
able, possibility to monitor and treat the coagulation
disorders before, during, and after the procedure and,
Figure 3. The three patients facing the most severe grade IV to V complications. Top panel: A 9-year-old boy with an extensive and
diffuse venous malformation (VM) of the retroperitoneum, paraspinal muscles, and spinal canal. VM dislocates the right kidney
anteriorly and causes mild hydronephrosis in the left kidney. T2-weighted fat-saturated axial magnetic resonance (MR) image before
(a) and after (b) several procedures shows reduction of the mass. Angiography image of bleeding from the phrenic artery, complicating
sclerotherapy of the lesion (c). Middle panel: A 45-year-old man with extensive infiltrating VM in the pelvis, perineum, and right thigh.
A large malformation mass hangs from the perineum (d). Extent of the lesion in T2-weighted fat-saturated axial MR image (e).
Fluoroscopy image of the sclerotherapy procedure reveals wide venous structures filled with contrast material (f). Bottom panel:
A 32-year-old woman with extensive VM involving the entire right arm and axilla (g). T2-weighted fat-saturated coronal MR image
shows the lesion extending into the thorax cavity (h). CT image of a fatal multifocal intracerebral haemorrhage after the sclerotherapy
procedure (i).
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when necessary, the available option of ICU
treatment. This concerns, however, only a small minor-
ity of VMs.
The total complication rate in our tertiary care unit
(12.5% of the procedures and 24.4% of the patients)
corresponded to earlier ﬁgures (Table 1). Reported
complication rates vary greatly, however, depending
on sclerosants, patient selection, and deﬁnition of com-
plication, which makes comparison diﬃcult. Gulsen
et al.27, for example, report polidocanol sclerotherapy
data with a complication rate of 65%, considering pain
and swelling as minor complications, while Tan et al.24
report, for STS sclerotherapy, a complication rate of
only 9.7%. Our complication rates for each of these
two sclerosants were equal (11%). The complication
risk has been signiﬁcantly higher with ethanol than
with bleomycine.15 We showed the risk from ethanol
as being signiﬁcantly higher also than that of detergents
which are now commonly used sclerosants in many cen-
ters. Compared to deep lesion location, subcutaneous
location constituted a higher complication risk with
both ethanol and detergent sclerosants; this corres-
ponded to others’ ﬁndings with ethanol.25,26
The high variability of complication rates is appar-
ently due to the lack of uniform deﬁnition and classiﬁ-
cation of complications. Many of the reports apply no
classiﬁcation at all,5,15,25,29,30 or they divide complica-
tions into local and systemic28 or major and
minor,23,24,27 without clearly deﬁning these descrip-
tions. The Clavien–Dindo classiﬁcation, applied in
this study, is previously used in one report on head
and neck VM sclerotherapy complications.33
The risk for skin damage is higher in superﬁcial than
in deeper lesions. Although it can be reduced by using
low concentration polidocanol foam, these complica-
tions still occur. They mostly heal well, but cause tran-
sient discomfort and scarring. This emphasizes the
importance of patient counselling: each patient must
know the risk for skin damage beforehand, and risk
should be carefully weighed against symptoms.35
When evaluating indications for treatment, one essen-
tial factor is correct diagnosis. For example, two of our
patients with prolonged pain and swelling as complica-
tions, obviously had ﬁbro-adipose vascular anomaly
(FAVA)38; based on our current knowledge, they
should have received no sclerotherapy.
An experimental study with rat femoral vein model
has shown that in intraluminal administration, variable
amounts of sclerotic agents leak in into surrounding
tissues, which may have detrimental eﬀects on adjacent
nerves.39 This entails risk for neural damage, especially
in restricted muscle compartments. We had, however,
only a single neural complication, which was transient
sensory loss in one ﬁnger. In a systematic review of
1214 patients, the risk for neural damage after VM
sclerotherapy was 1.85%.40 Contrary to common
belief, neural complications are thus fairly rare.
In patients undergoing several sclerotherapy procedures
or previous surgical treatment, the complication rate
showed no increase, nor did patient age or malformation
location inﬂuence complication rate. Complications thus
seem to be independent events inﬂuenced mainly by
lesion morphology and depth. The relatively low patient
number, however, ampliﬁes uncertainty regarding these
negative results.
Evaluation of treatment outcomes was beyond the
scope of this study. It turned out to be unreliable based
on patient records and thus deserves its own prospect-
ive study.
Study limitations were mainly related to its retro-
spective nature. Severity and duration of pain and swel-
ling were diﬃcult to assess on the basis of patient
records. Typically, the patient had had similar symp-
toms prior to the treatment, and whether they were
exacerbated by the sclerotherapy was not evident in
every case. During the study period, we have used a
wide variety of devices such as diﬀerent needles, syr-
inges, catheters, introducers, and vascular access kits.
The selection of equipment has based on the speciﬁc
anatomy of each lesion and the availability of the
equipment over the years. We were not able to specify
the source of all equipment used. Any methodological
weaknesses could be lessened by collecting data on the
patients and the procedures systematically and pro-
spectively. For these purposes, we are now setting up
a patient registry for vascular anomalies with auto-
mated data collection. Moreover, the conﬁdence
regarding risks with various sclerosants was limited
by numbers of patients and procedures.
Finally, one should note that a sclerotherapy compli-
cation does not necessarily mean unsuccessful treatment,
and despite any complication, patients often consider the
overall outcome as satisfactory. Regarding the risk for
complications, all VMs do not necessarily have to be
treated, especially those causing only mild cosmetic
harm. On the other hand, some malformations should
only be treated in centres prepared to manage the poten-
tially very severe complications. Beneﬁts and risks must
be weighed in each case in a multidisciplinary setting.
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